Background: While popularly consumed for its perceived benefits as a sleeping aid, the impact of cannabis on sleep-wake regulation in clinical studies is inconclusive. The purpose of this study was to determine the relationship between cannabis use and nightly sleep duration in a nationally representative dataset.
Methods: A cross-sectional analysis of adults was undertaken using the National Health and Nutrition Examination Survey data from 2005 to 2018. Respondents were dichotomized as recent users or non-users if they had used or not used cannabis in the past 30 days, respectively. The primary outcome was nightly sleep duration, categorized as short (<6 hours), optimal (6-9 hours), and long (>9 hours). Multinomial logistic regression was used to adjust for sociodemographic and health-related covariates, and survey sample weights were used in modeling.
Results: From a sample representing approximately 146 million adults in the USA, 14.5% reported recent cannabis use. In an adjusted analysis, recent users were more likely than non-users to report both short sleep (OR 1.34, 95% CI 1.12 to 1.59, p<0.001) and long sleep (OR 1.56, 95% CI 1.25 to 1.96, p<0.001). Heavy users (≥20 of the past 30 days) were even more likely to be at the extremes of nightly sleep duration.
Discussion: Recent cannabis use was associated with the extremes of nightly sleep duration in a nationally representative sample of adults, with suggestions of a dose-response relationship. Our findings highlight the need to further characterize the sleep health of regular cannabis users in the population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/rapm-2021-103161 | DOI Listing |
J Pineal Res
November 2024
Healthy Brain Ageing Program, Brain and Mind Centre, School of Psychology, The University of Sydney, Sydney, New South Wales, Australia.
Melatonin has multiple proposed therapeutic benefits including antioxidant properties, circadian rhythm synchronisation and sleep promotion. Since these areas are also recognised risk factors for dementia, melatonin has been hypothesised to slow cognitive decline in older adults. Participants with Mild Cognitive Impairment (MCI) were recruited from the community for a 12-week randomised placebo-controlled parallel, feasibility trial of 25 mg oral melatonin nightly.
View Article and Find Full Text PDFFront Psychiatry
November 2024
Attune Neurosciences, Bel Air, MD, United States.
Introduction: Opioid use disorder (OUD) is a serious and persistent problem in the United States with limited non-pharmacological treatment options, especially for the concomitant sleep disorders experienced by most individuals with addiction. While new, non-invasive interventions such as low-intensity focused ultrasound (LIFU) have shown promise in targeting the brain regions impacted throughout addiction and recovery, the devices used are not amenable to outpatient treatment in their current form factor and cannot be used at night during sleep. To bridge this gap and provide a much-needed treatment option for repeated, at-home use, we developed a wearable LIFU device out-of-clinic use.
View Article and Find Full Text PDFChild Dev
December 2024
Fordham University, New York, New York, USA.
Crime impacts both the immediate victims and has indirect effects on the community. This study examined associations between daily neighborhood crime and actigraphy-assessed sleep outcomes using multilevel modeling. Data were from a longitudinal (14-day) study of 288 adolescents (M = 15.
View Article and Find Full Text PDFLaryngoscope
November 2024
Department of Otolaryngology, Massachusetts Eye and Ear, Boston, Massachusetts, U.S.A.
Sleep
November 2024
Epilepsy and Neuropharmacology Clinical Trials Unit, Alfred Brain, Alfred Health, Melbourne, Victoria, Australia.
Study Objectives: Current treatments for obstructive sleep apnoea (OSA) are ineffective or not tolerated in a proportion of patients. Other therapeutic options are needed and pharmaceuticals may provide an alternative. This randomised, double-blind, placebo-controlled, cross-over study examined the effect of combination acetazolamide and dronabinol (IHL-42X) at low, medium and high doses on OSA severity.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!